| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_2658d45a8e9c71b9598e2bf83242bab3
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_ccb24622c95e1b68421dfa789ac7ffe2
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_e2790d6b9542767e8c6d45ea102e9f96 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-5685
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-5011
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-225 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-22
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-50 |
| filingDate |
1995-08-07-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f98f8a242f6b445bc61bc22a1e721f0a
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d7fbf068dc32bf5a06442155220cc5c7 |
| publicationDate |
1996-02-15-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
WO-9603993-A2 |
| titleOfInvention |
Modulation of thymocyte and t cell functional activity |
| abstract |
The present invention relates to modulation of cell mediated immune responses, and to modulation or inhibition of thymocyte cancers or thymomas. In a first aspect, the present invention is directed to a method for suppressing an immune response by administering dehydroepiandrosterone (DHEA). In another aspect, the invention relates to a method for enhancing an immune response comprising administering an amount of an inhibitor of calcitonin gene related peptide (CGRP), such as the CGRP antagonist CGRP8-37, or an amount of an inhibitor of DHEA. The invention also provides a method for treating a thymic cancer or thymoma comprising administering an amount of calcitonin gene related peptide (CGRP) effective to induce apoptosis of thymic cancer or thymoma cells. The invention further provides a method for preventing tissue damage comprising administering an amount of an inhibitor of CGRP to inhibit apoptosis of cells in the area of the tissue damage. The invention also relates to a method for identifying an agent capable of inhibiting CGRP-mediated apoptosis. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-3184546-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-1033989-A4
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-0845269-A2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2010075238-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-8168592-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-1033989-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-3569620-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2019087161-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-0845269-A3 |
| priorityDate |
1994-08-05-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |